Allogeneic transplantation for myelofibrosis: Benefit of dose intensity.

Abstract Poster

Authors

null

Uday R. Popat

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Uday R. Popat , Roland Bassett Jr., Julianne Chen , Amin Majid Alousi , Paolo Anderlini , Stefan O. Ciurea , Chitra Hosing , Roy B. Jones , Partow Kebriaei , Issa F. Khouri , Sergej Konoplev , Marcos De Lima , Yago Nieto , Betul Oran , Muzaffar H. Qazilbash , Gabriela Rondon , Elizabeth J. Shpall , Srdan Verstovsek , Borje Andersson , Richard E. Champlin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Allogeneic Bone Marrow

Clinical Trial Registration Number

NCT00475020

Citation

J Clin Oncol 31, 2013 (suppl; abstr 7011)

DOI

10.1200/jco.2013.31.15_suppl.7011

Abstract #

7011

Poster Bd #

3

Abstract Disclosures

Similar Posters

Poster

2017 ASCO Annual Meeting

Allogeneic hematopoietic cell transplantation for myelofibrosis (MF) in high risk patients.

Allogeneic hematopoietic cell transplantation for myelofibrosis (MF) in high risk patients.

First Author: Swapna Narayana

First Author: Henry Jacob Conter

First Author: Eric Jay Feldman

First Author: N. Pemmaraju